A PHASE 2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162b2 RNA-BASED VACCINE CANDIDATES FOR SARS-CoV-2 NEW VARIANTS IN HEALTHY INDIVIDUALS
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- BioNTech SE
- 入组人数
- 1,051
- 试验地点
- 69
- 主要终点
- SSA: Percentage of participants reporting local reactions
研究概览
简要总结
The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of SARS-CoV-2 in healthy people.
Substudy A:
-
This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi XBB.1.5) given as a single 30 µg dose,
-
in people who are 12 years of age and older,
-
who previously received at least 3 doses of a US-authorized mRNA COVID-19 vaccine, with the most recent dose being an Omicron BA.4/BA.5-adapted bivalent vaccine received at least 150 days before the study vaccination (Visit 1).
-
The study is about 6 months long for each participant.
-
Participants will have at least 5 visits to the clinic.
-
At each clinic visit a blood sample will be taken.
-
At least 1 nasal swab will taken.
Substudy B:
-
This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi XBB.1.5) given as a single 30 µg dose,
-
in people who are 12 years of age and older,
-
who are COVID-19 vaccine-naïve
-
who have had any positive SARS-CoV-2 test result >28 days before study vaccine administration.
-
The study is about 6 months long for each participant.
-
Participants will have at least 5 visits to the clinic.
-
At each clinic visit a blood sample will be taken.
-
At least 1 nasal swab will taken.
Substudy C:
-
This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi JN.1) and BNT162b2 (Omi KP.2) given as a single 30 µg dose to:
-
Cohort 1: people who are 18 years of age and older, who will receive BNT162b2 (Omi JN.1), and,
-
Cohort 2: people who are 12 years of age and older, who will receive BNT162b2 (Omi JN.1), and,
-
Cohort 3: people who are 18 years of age and older who will receive BNT162b2 (Omi KP.2).
-
Participants may have never received a COVID-19 vaccine or, may have previously received COVID-19 vaccine(s), with the most recent dose received at least 150 days before the study vaccination (Visit 1).
-
The study is about 6 months long for each participant.
-
Participants will have at least 6 visits (Cohorts 1 and 3) or at least 5 visits (Cohort 2) to the clinic.
-
At each clinic visit a blood sample will be taken.
-
At least 1 nasal swab will taken.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
盲法说明
Open-label
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Inclusion Criteria:
- •Received at least 3 prior doses of a US-authorized mRNA COVID-19 vaccine, with the most recent dose being a US-authorized Omicron BA.4/BA.5-adapted bivalent vaccine received at least 150 days before Visit 1 (Day 1).
- •12 years of age and older
- •Healthy participants (stable pre-existing disease permitted).
- •Willing and able to comply with all scheduled visits/contacts, study procedures and lifestyle considerations.
- •Capable of giving, or parent(s)/legal guardian capable of giving, signed informed consent.
排除标准
- •History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study vaccines.
- •Immunocompromised with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
- •Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
- •Women who are pregnant or breastfeeding.
- •Any medical or psychiatric condition, or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- •History of myocarditis or pericarditis.
- •Receipt of systemic treatment with known immunosuppressant medications (including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease), or radiotherapy, within 60 days before enrollment or planned receipt through conclusion of the study.
- •Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, used for the treatment or prevention of COVID-19 or those that are considered immunosuppressive, from 60 days before study vaccination or planned receipt throughout the study.
- •Participation in other studies involving receipt of other study intervention within 28 days before enrollment. Anticipated participation in other studies involving other study intervention from enrollment through the end of this study.
- •Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
- •Inclusion Criteria:
- •COVID-19 vaccine-naïve.
- •Any positive SARS-CoV-2 test result >28 days before study intervention administration.
- •12 years of age and older.
- •Healthy participants (stable pre-existing disease permitted).
- •Willing and able to comply with all scheduled visits/contacts, study procedures and lifestyle considerations.
- •Capable of giving or parent(s)/legal guardian capable of giving, signed informed consent.
- •Exclusion Criteria:
- •History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study vaccines.
- •Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
- •Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
- •Women who are pregnant or breastfeeding.
- •Any medical or psychiatric condition, including recent (within the past year) or active suicidal ideation/behavior, or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- •History of myocarditis or pericarditis.
- •Receipt of systemic treatment with known immunosuppressant medications (including cytotoxic agents or systemic corticosteroids*, eg, for cancer or an autoimmune disease), or radiotherapy, within 60 days before enrollment or planned receipt through conclusion of the study.
- •Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies used for the treatment or prevention of COVID-19 or those that are considered immunosuppressive, from 60 days before study intervention administration or planned receipt throughout the study.
- •Participation in other studies involving receipt of other study intervention within 28 days before enrollment. Anticipated participation in other studies involving other study intervention from enrollment through the end of this study.
- •Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
- •Inclusion Criteria:
- •Cohort 1: 18 years of age and older
- •Cohort 2: 12 years of age and older
- •Cohort 3: 18 years of age and older
- •Healthy participants (stable pre-existing disease permitted).
- •Willing and able to comply with all scheduled visits/contacts, study procedures and lifestyle considerations.
- •Capable of giving, or parent(s)/legal guardian capable of giving, signed informed consent.
- •Exclusion Criteria
- •History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study vaccines.
- •Immunocompromised with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
- •Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
- •Women who are pregnant or breastfeeding.
- •Any medical or psychiatric condition, or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- •History of myocarditis or pericarditis.
- •Receipt of systemic treatment with known immunosuppressant medications (including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease), or radiotherapy, within 60 days before enrollment or planned receipt through conclusion of the study.
- •Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, used for the treatment or prevention of COVID-19 or those that are considered immunosuppressive, from 60 days before study vaccination or planned receipt throughout the study.
- •Receipt of a COVID-19 vaccine less than 150 days before study intervention administration Visit 1 (Day 1).
- •Participation in other studies involving receipt of other study intervention within 28 days before enrollment. Anticipated participation in other studies involving other study intervention from enrollment through the end of this study.
- •Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
研究组 & 干预措施
SSA: Group 1
Participants 12 years of age and older, COVID-19 vaccine-experienced will receive 30 µg of BNT162b2 (Omi XBB.1.5) at Visit 1.
干预措施: BNT162b2 (Omi XBB.1.5) (Biological)
SSB: Group 2
Participants 12 years of age and older who were previously exposed to SARS-CoV-2 and are COVID-19 vaccine-naïve will receive 30 μg of BNT162b2 (Omi XBB.1.5) at Visit 1
干预措施: BNT162b2 (Omi XBB.1.5) (Biological)
SSC: Group 3
Cohort 1 - Participants 18 years of age and older will receive 30 µg of BNT162b2 (Omi JN.1) at Visit 1.
干预措施: BNT162b2 (Omi JN.1) (Biological)
SSC: Group 4
Cohort 2 - Participants 12 years of age and older will receive 30 µg of BNT162b2 (Omi JN.1) at Visit 1.
干预措施: BNT162b2 (Omi JN.1) (Biological)
SSC - Group 5
Cohort 3 - Participants 18 years of age and older who will receive 30 µg of BNT162b2 (Omi KP.2) at Visit 1.
干预措施: BNT162b2 (Omi KP.2) (Biological)
结局指标
主要结局
SSA: Percentage of participants reporting local reactions
时间窗: For up to 7 days following the study vaccination
Pain at the injection site, redness, and swelling, as self-reported in electronic diaries.
SSA: Percentage of participants reporting systemic events
时间窗: For up to 7 days following the study vaccination
Fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain, as self-reported in electronic diaries
SSA: Percentage of participants reporting adverse events
时间窗: Through 1 month after the study vaccination
As elicited by the investigational staff
SSA: Percentage of participants reporting serious adverse events
时间窗: Through 6 months after the study vaccination
As elicited by the investigational staff
SSA: Geometric Mean Titers (GMT) of SARS-CoV-2 Omicron XBB.1.5- and Omicron BA.4/BA.5-neutralizing antibody levels for BNT162b2 (Omi XBB.1.5) 30 µg
时间窗: At 1 month after the study vaccination
As measured at the central laboratory
SSA: Geometric Mean Fold Rise (GMFR; change between 2 timepoints) of SARS-CoV-2 Omicron XBB.1.5-and Omicron BA.4/BA.5-neutralizing antibody levels for BNT162b2 (Omi XBB.1.5) 30 µg
时间窗: From before study vaccination (Day 1) to 1 month after study vaccination
As measured at the central laboratory
SSA: Percentages of participants with seroresponse to BNT162b2 (Omi XBB.1.5) 30 µg in terms of GMTs of SARS-CoV-2 Omicron XBB.1.5- and Omicron BA.4/BA.5-neutralizing antibody levels
时间窗: At 1 month after the study vaccination
As measured at the central laboratory
SSB: Percentage of participants reporting local reactions
时间窗: For up to 7 days following the study vaccination
Pain at the injection site, redness, and swelling, as self-reported in electronic diaries.
SSB: Percentage of participants reporting systemic events
时间窗: For up to 7 days following the study vaccination
Fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain, as self-reported in electronic diaries.
SSB: Percentage of participants reporting adverse events
时间窗: Through 1 month after the study vaccination
As elicited by the investigational staff.
SSB: Percentage of participants reporting serious adverse events
时间窗: Through 6 months after the study vaccination
As elicited by the investigational staff.
SSB: Geometric Mean Ratio (GMR) of the SARS-CoV-2 XBB.1.5-neutralizing titers after BNT162b2 (Omi XBB.1.5) 30 μg given as single dose to COVID-19 vaccine-naïve subjects to BNT162b2 (Omi XBB.1.5) 30 μg given to vaccine-experienced participants in SSA.
时间窗: At 1 month after vaccination.
As measured at the central laboratory
Difference in percentages of subjects with seroresponse to XBB.1.5 strain after BNT162b2 (Omi XBB.1.5) 30 μg given as single dose to COVID-19 vaccine-naïve subjects compared to BNT162b2 (Omi XBB.1.5) 30 μg given to vaccine experienced subjects in SSA
时间窗: At 1 month after vaccination
As measured at the central laboratory
SSC Cohort 1 and Cohort 2 combined: Percentage of participants reporting local reactions
时间窗: For up to 7 days following the study vaccination
Pain at the injection site, redness, and swelling, as self-reported in electronic diaries.
SSC Cohort 1 and Cohort 2 combined: Percentage of participants reporting systemic events
时间窗: For up to 7 days following the study vaccination
Fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain, as self-reported in electronic diaries
SSC Cohort 1 and Cohort 2 combined: Percentage of participants reporting adverse events
时间窗: Through 1 month after the study vaccination
As elicited by the investigational staff
SSC Cohort 1 and Cohort 2 combined: Percentage of participants reporting serious adverse events
时间窗: Through 6 months after the study vaccination
As elicited by the investigational staff
SSC Cohort 1 and Cohort 2 combined: Geometric Mean Titers (GMT) of SARS-CoV-2 Omicron JN.1- and Omicron XBB.1.5- neutralizing antibody levels for BNT162b2 (Omi JN.1) 30 µg.
时间窗: At 1 month after the study vaccination
As measured at the central laboratory
SSC Cohort 1 and Cohort 2 combined: Geometric Mean Fold Rise (GMFR; change between 2 timepoints) of SARS-CoV-2 Omicron JN.1- and Omicron XBB.1.5- neutralizing antibody levels for BNT162b2 (Omi JN.1) 30 µg.
时间窗: From before study vaccination (Day 1) to 1 month after study vaccination
As measured at the central laboratory
SSC Cohort 1 and Cohort 2 combined: Percentages of participants with seroresponse to BNT162b2 (Omi JN.1) 30 µg in terms of GMTs of SARS-CoV-2 Omicron JN.1- and Omicron XBB.1.5-neutralizing antibody levels.
时间窗: At 1 month after the study vaccination
As measured at the central laboratory
SSC Cohort 3: Percentage of participants reporting local reactions
时间窗: For up to 7 days following the study vaccination
Pain at the injection site, redness, and swelling, as self-reported in electronic diaries.
SSC Cohort 3: Percentage of participants reporting systemic events
时间窗: For up to 7 days following the study vaccination
Fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain, as self-reported in electronic diaries
SSC Cohort 3: Percentage of participants reporting adverse events
时间窗: Through 1 month after the study vaccination
As elicited by the investigational staff
SSC Cohort 3: Percentage of participants reporting serious adverse events
时间窗: Through 6 months after the study vaccination
As elicited by the investigational staff
SSC Cohort 3: Geometric Mean Titers (GMT) of SARS-CoV-2 Omicron KP.2- and Omicron JN.1- neutralizing antibody levels for BNT162b2 (Omi KP.2) 30 µg.
时间窗: At 1 month after the study vaccination
As measured at the central laboratory
SSC Cohort 3: Geometric Mean Fold Rise (GMFR; change between 2 timepoints) of SARS-CoV-2 Omicron KP.2- and Omicron JN.1- neutralizing antibody levels for BNT162b2 (Omi KP.2) 30 µg.
时间窗: From before study vaccination (Day 1) to 1 month after study vaccination
As measured at the central laboratory
SSC Cohort 3: Percentages of participants with seroresponse to BNT162b2 (Omi KP.2) 30 µg in terms of GMTs of SARS-CoV-2 Omicron KP.2- and Omicron JN.1- neutralizing antibody levels.
时间窗: At 1 month after the study vaccination
As measured at the central laboratory
Percentage of Participants With Local Reactions Within 7 Days After Vaccination: SSA
时间窗: Day 1 to Day 7 after vaccination
Local reactions: pain at injection site, redness and swelling were recorded by participants in an electronic diary (e-diary) or as adverse events (AEs) in the case report form (CRF). Redness and swelling were recorded in measuring device units (mdu) (range: 1 to 21), 1 mdu =0.5 centimeter (cm) and were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] and necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 local reactions were classified by investigator or medically qualified person.
Percentage of Participants With Systemic Events Within 7 Days After Vaccination: SSA
时间窗: Day 1 to Day 7 after vaccination
Systemic events were recorded by participants in an e-diary or as AEs in the CRF. Fever: defined as oral temperature more than or equal to (\>=38) degree Celsius (C) and categorized as \>= 38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, chills, new or worsened muscle pain and joint pain were graded as: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \>2 times in 24h, severe: required intravenous (IV) hydration. Diarrhea was graded as: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h. Grade 4 for all events except fever: ER visit/hospitalization. Grade 4 systemic events were classified by investigator or medically qualified person.
Percentage of Participants With Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination: SSA
时间窗: From vaccination on Day 1 up to 1 month after vaccination
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. A serious AE (SAE) was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event. AEs included both SAEs and all non-SAEs. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
Percentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSA
时间窗: From vaccination on Day 1 up to 6 months after vaccination
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event.
Geometric Mean Titers (GMT) of SARS-CoV-2 Omi XBB.1.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044
时间窗: At 1 month after vaccination
GMTs and 2-sided 95 percentage (%) confidence interval (CIs) were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\*LLOQ.
Percentage of Participants With Systemic Events Within 7 Days After Vaccination: SSC Cohort 2; SSC Cohort 1 and 2 Combined
时间窗: Day 1 to Day 7 after vaccination
Systemic events were recorded by participants in an e-diary or as AEs in the CRF. Fever: defined as oral temperature \>=38 degree C and categorized as \>= 38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, chills, new or worsened muscle pain and joint pain were graded as: mild (didn't interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild: 1-2 times in 24h, moderate: \>2 times in 24h, severe: required IV hydration. Diarrhea were graded as: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h. Grade 4 for all events except fever: ER visit/hospitalization. Grade 4 systemic events were classified by investigator or medically qualified person.
GMT of SARS-CoV-2 Omi BA.4/BA.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044
时间窗: At 1 month after vaccination
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Omi XBB.1.5-Neutralizing Titers From Before Study Vaccination to 1 Month After Vaccination: SSA and Historical Control of Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044
时间窗: From before vaccination on Day 1 up to 1 month after vaccination
GMFRs were defined as geometric mean ratios of the results after vaccination to the results before vaccination. GMFR and 2-sided 95% CI were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
GMFR of SARS-CoV-2 Omi BA.4/BA.5-Neutralizing Titers From Before Vaccination to 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044
时间窗: From before vaccination on Day 1 up to 1 month after vaccination
GMFRs were defined as geometric mean ratios of the results after vaccination to the results before vaccination. GMFR and 2-sided 95% CI were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Percentage of Participants With Seroresponse to SARS-CoV-2 Omi XBB.1.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044
时间窗: At 1 month after vaccination
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the LLOQ, the postvaccination assay result of \>= 4\* LLOQ was considered a seroresponse.
Percentage of Participants With Seroresponse to SARS-CoV-2 Omi BA.4/BA.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044
时间窗: At 1 month after vaccination
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the LLOQ, the postvaccination assay result of \>= 4\* LLOQ was considered a seroresponse.
Percentage of Participants With Local Reactions Within 7 Days After Vaccination: SSB
时间窗: Day 1 to Day 7 after vaccination
Local reactions: pain at injection site, redness and swelling were recorded by participants in an e-diary or as AEs in the CRF. Redness and swelling were recorded in mdu (range:1 to 21), 1 mdu= 0.5 cm and were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] and necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 local reactions were classified by investigator or medically qualified person.
Percentage of Participants With Systemic Events Within 7 Days After Vaccination: SSB
时间窗: Day 1 to Day 7 after vaccination
Systemic events were recorded by participants in an e-diary or as AEs in the CRF. Fever: defined as oral temperature \>=38 degree C and categorized as \>= 38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, chills, new or worsened muscle pain and joint pain were graded as: mild (didn't interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild: 1-2 times in 24h, moderate: \>2 times in 24h, severe: required IV hydration. Diarrhea were graded as: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h. Grade 4 for all events except fever: ER visit/hospitalization. Grade 4 systemic events were classified by investigator or medically qualified person.
Percentage of Participants With AEs From Vaccination Through 1 Month After Vaccination: SSB
时间窗: From vaccination on Day 1 up to 1 month after vaccination
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event. AEs included both SAEs and all non-SAEs. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
Percentage of Participants With AEs From Vaccination Through 1 Month After Vaccination: SSC Cohort 2; SSC Cohort 1 and 2 Combined
时间窗: From vaccination on Day 1 up to 1 month after vaccination
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event. AEs included both SAEs and all non-SAEs. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
Percentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSB
时间窗: From vaccination on Day 1 up to 6 months after vaccination
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event.
Geometric Mean Ratio (GMR) of the SARS-CoV-2 XBB.1.5-Neutralizing Titers 1 Month After BNT162b2 (Omi XBB.1.5) COVID-19 Vaccine-Naive Participants in SSB Versus Vaccine-Experienced Participants in SSA
时间窗: At 1 month after vaccination
GMTs / GMRs and 2-sided 95% CIs were calculated by exponentiating the least square (LS) means / difference of LS means and the corresponding CIs based on analysis of log-transformed assay results using a linear regression model with baseline assay results (log scale), age and vaccine group as covariates. Assay results below the LLOQ were set to 0.5\*LLOQ. GMT was reported in descriptive section and GMR was reported in statistical analysis section
Percentage of Participants and Difference in Percentage of Participants With Seroresponse to the XBB.1.5 Strain 1 Month After BNT162b2 (Omi XBB.1.5) COVID-19 Vaccine Naive Participants in SSB Versus Vaccine-Experienced Participants in SSA
时间窗: At 1 month after vaccination
Seroresponse was defined as achieving \>=4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the LLOQ, the postvaccination assay result of \>= 4\* LLOQ was considered a seroresponse. Percentage of participants with seroresponse were reported in descriptive section and difference in percentage of participants with seroresponse in SSB: All Age Groups (Vaccine Naive)- SSA: All Age Groups (Vaccine Experienced Control) were reported in statistical analysis section.
Percentage of Participants With Local Reactions Within 7 Days After Vaccination: SSC Cohort 2; SSC Cohort 1 and 2 Combined
时间窗: Day 1 to Day 7 after vaccination
Local reactions: pain at injection site, redness and swelling were recorded by participants in an e-diary or as AEs in the CRF. Redness and swelling were recorded in mdu (range:1 to 21), 1 mdu= 0.5 cm and were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] and necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 local reactions were classified by investigator or medically qualified person.
Percentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSC Cohort 2; SSC Cohort 1 and 2 Combined
时间窗: From vaccination on Day 1 up to 6 months after vaccination
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event.
Percentage of Participants With Local Reactions Within 7 Days After Vaccination: SSC Cohort 3
时间窗: Day 1 to Day 7 after vaccination
Local reactions: pain at injection site, redness and swelling were recorded by participants in an e-diary or as AEs in the CRF. Redness and swelling were recorded in mdu (range:1 to 21), 1 mdu= 0.5 cm and were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] and necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 local reactions were classified by investigator or medically qualified person.
Percentage of Participants With Systemic Events Within 7 Days After Vaccination: SSC Cohort 3
时间窗: Day 1 to Day 7 after vaccination
Systemic events were recorded by participants in an e-diary or as AEs in the CRF. Fever: defined as oral temperature \>=38 deg C and categorized as \>= 38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and joint pain: mild (didn't interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild: 1-2 times in 24h, moderate: \>2 times in 24h, severe: required IV hydration. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h. Grade 4 for all events except fever: ER visit/hospitalization. Grade 4 events were classified by investigator or medically qualified person.
Percentage of Participants With AEs From Vaccination Through 1 Month After Vaccination: SSC Cohort 3
时间窗: From vaccination on Day 1 up to 1 month after vaccination
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event. AEs included both SAEs and all non-SAEs. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
Percentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSC Cohort 3
时间窗: From vaccination on Day 1 up to 6 months after vaccination
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event.
GMTs of SARS-CoV-2 Omi JN.1 and XBB.1.5 Variant-Neutralizing Titers at 1 Month After Vaccination in SSC Cohorts 1 + 2 Combined and Historical Control Group From SSA
时间窗: At 1 month after vaccination
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
GMFR of SARS-CoV-2 Omi JN.1 and XBB.1.5 Variant-Neutralizing Titers From Before Vaccination to 1 Month After Vaccination in SSC Cohorts 1 + 2 Combined and Historical Control Group From SSA
时间窗: From before Vaccination to 1 month after Vaccination
GMFRs were defined as geometric mean ratios of the results after vaccination to the results before vaccination. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis.
Percentage of Participants With Seroresponse to SARS-CoV-2 OMI JN.1 and XBB.1.5 Variant-Neutralizing Titers at 1 Month After Vaccination in SSC Cohorts 1 + 2 Combined and Historical Control Group From SSA
时间窗: At 1 month after vaccination
Seroresponse was defined as achieving a \>=4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4 \*LLOQ is considered a seroresponse.
GMTs of SARS-CoV-2 Omi KP.2 and Omi JN.1 Variant-Neutralizing Titers at 1 Month After Vaccination in SSC Cohort 3 and SSC Cohorts 1 + 2 Combined as Control
时间窗: At 1 month after vaccination
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
GMFR of SARS-CoV-2 Omi KP.2 and Omi JN.1 Variant-Neutralizing Titers From Before Vaccination to 1 Month After Vaccination in SSC Cohort 3 and Cohorts 1 + 2 Combined as Control
时间窗: From before vaccination on Day 1 up to 1 month after vaccination
GMFRs were defined as geometric mean ratios of the results after vaccination to the results before vaccination. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis.
Percentage of Participants With Seroresponse to SARS-CoV-2 Omi KP.2 and Omi JN.1 Variant-Neutralizing Titers at 1 Month After Vaccination in SSC Cohort 3 and Cohorts 1 + 2 Combined as Control
时间窗: At 1 month after vaccination
Seroresponse was defined as achieving a \>=4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4 \*LLOQ is considered a seroresponse.
次要结局
未报告次要终点